These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2. Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; Jacob HS Trans Assoc Am Physicians; 1987; 100():21-7. PubMed ID: 3502662 [TBL] [Abstract][Full Text] [Related]
7. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer. Lee K; O'Donnell RW; Cockett AT J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620 [TBL] [Abstract][Full Text] [Related]
8. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. Kalland T; Belfrage H; Bhiladvala P; Hedlund G J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566 [TBL] [Abstract][Full Text] [Related]
9. Interleukin 2-activated cytotoxic lymphocytes in cancer therapy. Grimm EA; Jacobs SK; Lanza LA; Melin G; Roth JA; Wilson DJ Symp Fundam Cancer Res; 1986; 38():209-19. PubMed ID: 3489259 [TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique. Favrot MC; Coze C; Combaret V; Gaspard M; Colin C; Franks C; Negrier S; Philip I; Philip T Mol Biother; 1990 Mar; 2(1):32-7. PubMed ID: 2185792 [TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989 [TBL] [Abstract][Full Text] [Related]
12. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity. Kaufmann Y; Levanon M; Davidsohn J; Ramot B J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. Rosenberg SA J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777 [TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy of tumors using interleukin-2 and lymphokine-activated killer cells]. Jost LM; Gmür J; Oelz O; Sauter C; Stahel RA Schweiz Med Wochenschr; 1988 Feb; 119(5):137-43. PubMed ID: 3266369 [TBL] [Abstract][Full Text] [Related]
15. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491 [TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Papa MZ; Mulé JJ; Rosenberg SA Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517 [TBL] [Abstract][Full Text] [Related]
17. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells]. Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026 [TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630 [TBL] [Abstract][Full Text] [Related]
19. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells]. Taguchi T; Domoto K Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428 [TBL] [Abstract][Full Text] [Related]
20. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells. Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]